Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + caffeine + chlorpheniramine (Pharmex)
- Development stage
- Unknown
- Lead developer
- Pharmex Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Paracetamol + caffeine + chlorpheniramine is an approved, fixed-dose combination small molecule drug used for the symptomatic relief of cold and flu symptoms, such as fever, headache, rhinorrhea, sneezing, and watery eyes. The combination consists of three active ingredients: paracetamol (acetaminophen), an analgesic and antipyretic that acts by inhibiting cyclooxygenase (COX) enzymes in the central nervous system; caffeine, a central nervous system stimulant that blocks adenosine receptors and enhances the analgesic efficacy of paracetamol; and chlorpheniramine (chlorphenamine), a first-generation H1 antihistamine that competitively inhibits histamine H1 receptors and possesses anticholinergic activity to reduce nasal secretions. It is marketed under brand names such as Calmagrip Forte by Pharmex.
- Brand names
- Calmagrip ForteSedalmerck Max
- Other names
- acetaminophen + caffeine + chlorphenamineacetaminophen + caffeine + chlorpheniramineparacetamol + cafeína + clorfenaminaparacetamol + caffeine + chlorphenamineparacetamol/cafeína/clorfenaminaparacetamol/caffeine/chlorpheniramine
02
Targets
ADORA2A (Adenosine A₂A Receptor)ADORA3 (Adenosine A3 receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on paracetamol + caffeine + chlorpheniramine (Pharmex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + caffeine + chlorpheniramine (Pharmex).